Search - tctmd.com

Displaying 201 - 220 of 532

Sort: Relevancy | Date

Presentation Fellows 2017

The History of Reperfusion Therapies in STEMI: How Far Weve Come

Presenter: Ajay J. Kirtane, Gregg W. Stone

April 07, 2017

Presentation Fellows 2017

Bioresorbable Stent Technology: The Next Frontier?

Presenter: Ajay J. Kirtane, Gregg W. Stone

April 07, 2017

Presentation CHIP Washington DC 2017

A Brief Update of PCI for Left Main Disease: Perspectives After the EXCEL and NOBLE Trials

Presenter: Gregg W. Stone

March 21, 2017

Presentation JIM 2017

Bioresorbable Scaffolds: A Real Clinical Need? Yes!

Presenter: Gregg W. Stone

February 10, 2017

Presentation JIM 2017

Bioresorbable Scaffolds: An Important Clinical Need

Presenter: Gregg W. Stone

February 08, 2017

Presentation JIM 2017

FANTOM: A Radio-opaque Desaminotyrosine Polycarbonate-based Scaffold

Presenter: Gregg W. Stone

February 08, 2017

Presentation JIM 2017

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

Presenter: Gregg W. Stone

February 08, 2017

Presentation TCT 2016

Learnings From A Pivotal Transcatheter Mitral Device Trial: Can The MVARC/COAPT Paradigm Be Shortened?

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Gregg W. Stone

November 01, 2016

Presentation TCT 2016

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

Presentation TCT 2016

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

Presenter: Gregg W. Stone, Ron Waksman, John A. Ambrose

November 01, 2016

Presentation TCT 2016

Put Away Your Catheters! Nanomedicines to Treat Vulnerable Plaque

Presenter: Gregg W. Stone, Ron Waksman, Jonathan Leor

November 01, 2016

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

To Treat or Not to Treat (Focally): From Stable to PROSPECT-ABSORB and PREVENT

Presenter: Gregg W. Stone, Ron Waksman, Seung-Jung Park

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds for Vulnerable Plaque Treatment: Rationale for Focal Therapy, Early Clinical Experiences, and Will it Succeed?!

Presenter: Gregg W. Stone, Ron Waksman, Vasim Farooq

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Revascularize This Patient?

Presenter: John D. Puskas, Gregg W. Stone, Michael E. Halkos

November 01, 2016

Presentation TCT 2016

Case Introduction: How Would You Revascularize This Patient?

Presenter: John D. Puskas, Gregg W. Stone, Michael E. Halkos

November 01, 2016

Presentation TCT 2016

Announcing the NIH-sponsored HYBRID Revascularization Trial

Presenter: John D. Puskas, Gregg W. Stone

November 01, 2016

Advertisement

The History of Reperfusion Therapies in STEMI: How Far Weve Come

Bioresorbable Stent Technology: The Next Frontier?

A Brief Update of PCI for Left Main Disease: Perspectives After the EXCEL and NOBLE Trials

Bioresorbable Scaffolds: A Real Clinical Need? Yes!

Bioresorbable Scaffolds: An Important Clinical Need

FANTOM: A Radio-opaque Desaminotyrosine Polycarbonate-based Scaffold

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

Learnings From A Pivotal Transcatheter Mitral Device Trial: Can The MVARC/COAPT Paradigm Be Shortened?

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

FDA Perspectives on Short DAPT IDE Trials

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

Put Away Your Catheters! Nanomedicines to Treat Vulnerable Plaque

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

To Treat or Not to Treat (Focally): From Stable to PROSPECT-ABSORB and PREVENT

Bioresorbable Scaffolds for Vulnerable Plaque Treatment: Rationale for Focal Therapy, Early Clinical Experiences, and Will it Succeed?!

Case Conclusion: How Did We Revascularize This Patient?

Case Introduction: How Would You Revascularize This Patient?

Announcing the NIH-sponsored HYBRID Revascularization Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content